Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on EDAP TMS (EDAP), Veru (VERU) and Kamada (KMDA) with bullish sentiments.<\/p>\n
EDAP TMS (EDAP)<\/p>\n
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on EDAP TMS today and set a price target of $12.00. The companys shares closed last Wednesday at $6.26.<\/p>\n
According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 28.8% and a 47.4% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Cellectar Biosciences.<\/p>\n
EDAP TMS has an analyst consensus of Moderate Buy, with a price target consensus of $12.50, implying a 92.3% upside from current levels. In a report issued on April 28, Piper Sandler also initiated coverage with a Buy rating on the stock with a $13.00 price target.<\/p>\n
See todays analyst top recommended stocks >><\/p>\n
Veru (VERU)<\/p>\n
Oppenheimer analyst Leland Gershell maintained a Buy rating on Veru today and set a price target of $24.00. The companys shares closed last Wednesday at $7.24.<\/p>\n
According to TipRanks.com, Gershell is a 3-star analyst with an average return of 2.1% and a 36.7% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.<\/p>\n
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Veru with a $23.50 average price target.<\/p>\n
Kamada (KMDA)<\/p>\n
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Kamada, with a price target of $11.00. The companys shares closed last Wednesday at $5.86, close to its 52-week low of $5.78.<\/p>\n
According to TipRanks.com, Fein is a 5-star analyst with an average return of 12.7% and a 47.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA American, Constellation Pharmaceuticals, and Global Blood Therapeutics.<\/p>\n
Currently, the analyst consensus on Kamada is a Moderate Buy with an average price target of $11.00.<\/p>\n
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.<\/p>\n
<\/p>\n
Visit link:<\/p>\n
Analysts Offer Insights on Healthcare Companies: EDAP TMS (EDAP), Veru (VERU) and Kamada (KMDA) - Smarter Analyst<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on EDAP TMS (EDAP), Veru (VERU) and Kamada (KMDA) with bullish sentiments. EDAP TMS (EDAP) H.C. Continue reading